According to filings with the U.S. Securities and Exchange Commission, Simbryo Technologies is raising up to $5,252,615.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Simbryo Technologies
Simbryo Technologies is a commercial-stage biotech company focused on accelerating paths to pregnancy by applying organoid medicine and artificial intelligence to fertility care. Using a patients own endometrial biopsy tissue, Simbryo creates personalized endometrial organoidstiny living models of the uterine lining and combines them with blastoids, model embryos, to directly recreate and test the implantation process in the lab, providing the worlds first direct measure of endometrial function and endometrial fertility. Working with leading research institutions and fertility clinics, the company has developed precision diagnostic platforms that quantify endometrial receptivity and deliver comprehensive, actionable reports for fertility specialists and patients, helping identify what is and isnt working in a given patients implantation process and guiding optimized treatment decisions. In addition to its clinical diagnostics, Simbryo maintains a unique biobank and databank that serve as a powerful in vitro testbed for novel fertility treatments and new discoveries in reproductive medicine, positioning the company as an innovator in endometrial diagnostics and reproductive health. Overall, Simbryo Technologies aims to set a new clinical standard in fertility medicine by providing personalized endometrial fertility assessments that improve IVF success rates and give patients greater confidence in their path to pregnancy.

To learn more, visit https://www.simbryotech.com/
LinkedIn: https://www.linkedin.com/company/gosimbryo

Contact:
Yael Katz, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.